Home » Topics » BioWorld Science, Cancer

BioWorld Science, Cancer
RSS

Merck describes improved chemotherapeutic agents

Feb. 7, 1997

Whole-body hyperthermia therapy enters clinic for new indication

Feb. 6, 1997

Sugen's TK antagonist enters phase II

Feb. 6, 1997

Antitumor prodrugs for ADEPT from Pharmachemie

Feb. 6, 1997

ChiRex and Cell Therapeutics sign supply agreement

Feb. 5, 1997

GeneMedicine IND approved

Feb. 4, 1997

Demeter receives funding for anticancer program

Feb. 4, 1997

Antineoplastic antibiotics isolated by Japanese investigators

Feb. 4, 1997

Merck & Co. continues to develop farnesyl protein transferase inhibitors

Feb. 4, 1997

Preclinical results indicate potential of new approach to treatment of solid tumors

Feb. 3, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 9, 2026.
‘Target-high but uptake-defective’ state identified in ADC resistance
BioWorld
Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...
Hyperexcitability may be joint problem in epilepsy, dementia
BioWorld
The majority of epilepsies are developmental disorders that start in childhood. But there is a large minority that starts in late adulthood. And increasingly,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
FENS 2026: Shedding light on the sheddome
BioWorld
At the recently opened FENS Forum 2026 in Barcelona – the Federation of European Neuroscience Societies’ flagship congress and Europe’s largest neuroscience...